Potential pharmacological approach in the regulation of angiotensin-II conversion enzyme and dipeptidyl-peptidase 4 in diabetic COVID-19 patients
The global pandemic caused by coronavirus disease 2019 (COVID-19) has caused more than 1 million deaths worldwide. Some vaccines in clinical trials have reached stage 3. In the meantime, the understanding of biological and pathophysiological mechanisms of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is still unclear, such as the role that angiotensin-II conversion enzyme (ACE-2) and dipeptidyl-peptidase 4 (DPP-IV) may play in patients with diabetes related to COVID-19. The individual with diabetes is a known COVID-19 risk patient. Probably, the pharmacological regulation of the angiotensin renin system and ACE-2 on the one hand, and of the incretin system and DPP-IV on the other hand, could represent a therapeutic route of fundamental importance to reduce the risk of SARS-CoV-2 infection or of severe complications caused by infection.
John Hopkins University. Available from: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6
World Health Organization (WHO). DRAFT landscape of COVID-19 candidate vaccines. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020 doi: 10.1007/s00134-020-05991-x. [Epub ahead of print]. DOI: https://doi.org/10.1007/s00134-020-05991-x
Vitiello A, Ferrara F. Correlation between renin-angiotensin system and severe acute respiratory syndrome coronavirus 2 infection: what do we know. Eur J Pharmacol 2020;883:173373. DOI: https://doi.org/10.1016/j.ejphar.2020.173373
Jian S, Yushun W, Chuming L. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci U S A 2020;117:11727-34. DOI: https://doi.org/10.1073/pnas.2003138117
Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect 2020;9:601-4. DOI: https://doi.org/10.1080/22221751.2020.1739565
Mannucci E, Pala L, Ciani S, et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005;48:1168-72. DOI: https://doi.org/10.1007/s00125-005-1749-8
Vitiello A, Ferrara F. Pharmacological agents to therapeutic treatment of cardiac injury caused by Covid-19. Life Sci 2020;262:118510. DOI: https://doi.org/10.1016/j.lfs.2020.118510
Vitiello A, Ferrara F. Therapeutic strategies for SARS-CoV-2 acting on ACE-2. Eur J Pharm Sci 2020;105579. DOI: https://doi.org/10.1016/j.ejps.2020.105579
Lambeir AM, Durinx C, Scharpe S, DeMeester I. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94.
Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003;82:53-73. DOI: https://doi.org/10.1078/0171-9335-00302
Lambeir AM. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003;40:209-94. DOI: https://doi.org/10.1080/713609354
Kaufman MB. ACE inhibitor-related angioedema: are your patients at risk?. P T. ? 2013;38:170-2.
- Abstract views: 255
- PDF: 140
- HTML: 0
Copyright (c) 2021 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.